



Contacts: Tularik Inc.  
Andrew J. Perlman, M.D., Ph.D.  
650-825-7000

Burns McClellan, Inc.  
Juling Chao (Media)  
415-352-6262  
John Nugent (Investors)  
212-213-0006

**For Immediate Release**

**Tularik Announces the Initiation of an Efficacy Study in Patients with Hepatocellular Carcinoma**

**South San Francisco, CA – July 27, 2000** – Tularik Inc. (NASDAQ: TLRK) today announced the initiation of a phase I/II efficacy study for its anti-cancer drug candidate, T67, in patients with hepatocellular carcinoma (HCC). T67 has a novel chemical structure that binds irreversibly to  $\beta$ -tubulin, which is a cellular building block of microtubules and is essential to cell division. Vincristine, paclitaxel and vinorelbine, which are widely used tubulin active agents, have clinically validated the concept of targeting  $\beta$ -tubulin.

However, over time, many tumors become resistant to these tubulin active agents and other anti-cancer drugs. This phenomenon is known as multidrug resistance (MDR). In preclinical experiments, T67 retains its activity against tumors and cell lines that are resistant to other drugs, including paclitaxel, by virtue of MDR. In the event that T67 has sufficient activity in refractory tumor types for which no other treatment exists, T67 may be a candidate for accelerated approval by the FDA.

“Phase I studies have defined a schedule that appears safe and is consistent with repeat dosing of patients. During the course of these studies, we observed a durable partial response with concomitant symptomatic improvement in a patient with HCC. This patient’s cancer had been unresponsive to three separate anti-cancer drug regimens,” stated Jackie Walling, Ph.D., Medical Director at Tularik. “Our excitement with T67 lies in its validated mechanism of action and in its potential to overcome MDR.”

Phase II studies will be conducted in cancer centers in the US, UK, Hong Kong, Taiwan and Canada. These studies will include patients with HCC, breast cancer, non-small cell lung cancer, colorectal cancer, glioma and lymphoma.

-more-

Tularik is engaged in the discovery and development of a broad range of novel and superior orally available drugs based on gene regulation. Tularik programs address cancer, CMV, diabetes, obesity, inflammation, allergy/asthma, lipid disorders and bacterial diseases, and a class of targets known as orphan nuclear receptors. Tularik has established strategic partnerships with Japan Tobacco Inc., Roche Bioscience and Knoll AG. For additional information, visit Tularik's Internet website at [www.tularik.com](http://www.tularik.com).

*Statements in this press release that are not strictly historical are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. There can be no assurance that Tularik will obtain necessary regulatory approvals for its drug candidates or be able to develop a commercially viable pharmaceutical product. These and other risks are more fully discussed in Tularik's SEC reports, including the report on Form 10-Q for the quarter ended March 31, 2000.*

###